CN101600426B - 用于治疗肠道疾病的异山梨醇单硝酸酯衍生物 - Google Patents

用于治疗肠道疾病的异山梨醇单硝酸酯衍生物 Download PDF

Info

Publication number
CN101600426B
CN101600426B CN2007800443012A CN200780044301A CN101600426B CN 101600426 B CN101600426 B CN 101600426B CN 2007800443012 A CN2007800443012 A CN 2007800443012A CN 200780044301 A CN200780044301 A CN 200780044301A CN 101600426 B CN101600426 B CN 101600426B
Authority
CN
China
Prior art keywords
compounds
intestinal
alkyl
general formula
mononitrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800443012A
Other languages
English (en)
Chinese (zh)
Other versions
CN101600426A (zh
Inventor
何塞·瑞波利斯莫利纳
弗朗西斯科·普比尔科伊
玛丽萨贝尔·莫瑞尔曼奇尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lacer SA
Original Assignee
Lacer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38043051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101600426(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lacer SA filed Critical Lacer SA
Publication of CN101600426A publication Critical patent/CN101600426A/zh
Application granted granted Critical
Publication of CN101600426B publication Critical patent/CN101600426B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2007800443012A 2006-12-28 2007-12-27 用于治疗肠道疾病的异山梨醇单硝酸酯衍生物 Expired - Fee Related CN101600426B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06380338A EP1941876A1 (en) 2006-12-28 2006-12-28 Isosorbide mononitrate derivatives for the treatment of Inflammation and ocular hypertension
EP06380338.1 2006-12-28
PCT/EP2007/064591 WO2008080955A1 (en) 2006-12-28 2007-12-27 Isosorbide mononitrate derivatives for the treatment of intestinal disorders

Publications (2)

Publication Number Publication Date
CN101600426A CN101600426A (zh) 2009-12-09
CN101600426B true CN101600426B (zh) 2012-07-25

Family

ID=38043051

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2007800443012A Expired - Fee Related CN101600426B (zh) 2006-12-28 2007-12-27 用于治疗肠道疾病的异山梨醇单硝酸酯衍生物
CNA2007800441623A Pending CN101600425A (zh) 2006-12-28 2007-12-27 用于治疗高眼压的单硝酸异山梨酯衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2007800441623A Pending CN101600425A (zh) 2006-12-28 2007-12-27 用于治疗高眼压的单硝酸异山梨酯衍生物

Country Status (21)

Country Link
US (1) US20080161389A1 (enExample)
EP (3) EP1941876A1 (enExample)
JP (2) JP2010514733A (enExample)
KR (2) KR20090112673A (enExample)
CN (2) CN101600426B (enExample)
AR (1) AR064543A1 (enExample)
AT (2) ATE484279T1 (enExample)
AU (2) AU2007341289B2 (enExample)
BR (2) BRPI0720663A2 (enExample)
CA (2) CA2674550A1 (enExample)
CL (2) CL2007003836A1 (enExample)
DE (2) DE602007009877D1 (enExample)
ES (3) ES2324130B1 (enExample)
IL (2) IL198912A0 (enExample)
MX (2) MX2009007040A (enExample)
NO (2) NO20092763L (enExample)
PL (2) PL2114398T3 (enExample)
RU (2) RU2009128970A (enExample)
UY (1) UY30847A1 (enExample)
WO (2) WO2008080939A1 (enExample)
ZA (2) ZA200903566B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2149577B1 (en) * 2008-07-22 2011-04-27 Lacer, S.A. New stereospecific method for the preparation of dioxa-bicyclooctane compounds
EP2149576A1 (en) * 2008-07-22 2010-02-03 Lacer, S.A. Isosorbide Nitrates having vasodilating activity
EP2177216A1 (en) * 2008-10-13 2010-04-21 Lacer, S.A. Use of dianhydrohexite mononitrate derivatives as healing agents
WO2010055138A1 (en) * 2008-11-14 2010-05-20 Lacer, S.A. New stereospecific method for the preparation of dioxa-bicyclooctane compounds
EP2199294A1 (en) * 2008-12-19 2010-06-23 Lacer, S.A. New stereospecific method for the preparation of dioxa bicyclooctane nitrate compounds
CA2822747A1 (en) * 2009-12-23 2011-06-30 Arca Biopharma, Inc. Use of s-(6-nitro-oxi-hexahydro-furo[3,2-b]thioacetate in the treatment of cardiovascular disorders associated with oxide synthase dysfunction
RU2015139514A (ru) * 2013-03-05 2017-04-07 Арчер Дэниелс Мидлэнд Компани Монотрифлаты изогексида и способ их синтеза
WO2018224419A1 (en) 2017-06-06 2018-12-13 Nicox S.A. Nitric oxide donating isomannide derivatives

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863905A (zh) * 2003-09-08 2006-11-15 得克萨斯系统大学董事会 通过用前列腺素或前列腺素类似物补充培养基加强体外胚发育的方法以及组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2739689C2 (de) * 1977-09-02 1986-10-16 Euratom Thermische Wärmepumpe
JPS60149521A (ja) * 1984-01-18 1985-08-07 Eisai Co Ltd 高眼圧・緑内障治療・予防用点眼剤
US5573758A (en) * 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US5925342A (en) * 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
GB9720797D0 (en) * 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
ES2142773B1 (es) * 1998-10-07 2001-01-01 Lacer Sa Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida.
JP2004517940A (ja) * 2001-01-31 2004-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ピラゾロ[4,3−d]ピリミジンおよびニトレートまたはチエノピリミジンおよびニトレートを含む医薬製剤
US20060264353A1 (en) * 2002-03-21 2006-11-23 Maxey Kirk M Prostaglandin f2alpha analogs and their use in combination with antimicrobial proteins for the treatment of glaucoma and intraocular hypertension
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863905A (zh) * 2003-09-08 2006-11-15 得克萨斯系统大学董事会 通过用前列腺素或前列腺素类似物补充培养基加强体外胚发育的方法以及组合物

Also Published As

Publication number Publication date
EP2114398A1 (en) 2009-11-11
EP2124930A1 (en) 2009-12-02
ZA200903566B (en) 2010-08-25
NO20092764L (no) 2009-07-27
RU2009128968A (ru) 2011-02-10
BRPI0720663A2 (pt) 2014-01-14
EP2114398B1 (en) 2010-06-30
ES2354317T3 (es) 2011-03-14
JP2010514733A (ja) 2010-05-06
AU2007341218B2 (en) 2010-09-09
MX2009007038A (es) 2009-08-25
ZA200903567B (en) 2010-08-25
IL198941A0 (en) 2010-02-17
ES2348314T3 (es) 2010-12-02
ES2324130B1 (es) 2010-03-22
CN101600425A (zh) 2009-12-09
ATE472324T1 (de) 2010-07-15
DE602007007523D1 (de) 2010-08-12
AU2007341289B2 (en) 2010-08-26
UY30847A1 (es) 2008-05-31
KR20090112673A (ko) 2009-10-28
PL2114398T3 (pl) 2010-11-30
WO2008080955A1 (en) 2008-07-10
BRPI0720664A2 (pt) 2014-01-14
RU2009128970A (ru) 2011-02-10
JP2010514734A (ja) 2010-05-06
WO2008080939A1 (en) 2008-07-10
NO20092763L (no) 2009-07-27
IL198912A0 (en) 2010-02-17
EP2124930B1 (en) 2010-10-13
CN101600426A (zh) 2009-12-09
CL2007003836A1 (es) 2008-07-11
PL2124930T3 (pl) 2011-04-29
KR20100100584A (ko) 2010-09-15
CA2674144A1 (en) 2008-07-10
AR064543A1 (es) 2009-04-08
ATE484279T1 (de) 2010-10-15
EP1941876A1 (en) 2008-07-09
ES2324130A1 (es) 2009-07-30
DE602007009877D1 (de) 2010-11-25
AU2007341218A1 (en) 2008-07-10
CL2007003837A1 (es) 2008-07-11
MX2009007040A (es) 2009-08-25
AU2007341289A1 (en) 2008-07-10
CA2674550A1 (en) 2008-07-10
US20080161389A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
CN101600426B (zh) 用于治疗肠道疾病的异山梨醇单硝酸酯衍生物
AU2014340182B2 (en) Cromolyn derivatives and related methods of imaging and treatment
CN111065390B (zh) Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途
US11433036B2 (en) Oxprenolol compositions for treating cancer
ES2886935T3 (es) Inhibidores de FASN para su uso en el tratamiento de esteatohepatitis no alcohólica
WO2018188641A1 (zh) 一种mor激动剂与kor激动剂的药物组合物及其用途
US11571411B2 (en) Use of a bisamide derivative of malonic acid for treating allergic and other diseases in humans and animals
BRPI0707089A2 (pt) derivados de camptotecina e seus usos
KR101082802B1 (ko) 8-하이드록시클로미프라민 또는 그의 염을 포함하는 조루의 예방 또는 치료용 약학 조성물
WO2019231739A1 (en) Compounds for pain treatment, compositions comprising same, and methods of using same
US20060189693A1 (en) Methods of treatment with lxr agonists
ES2332565B1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes antiinflamatorios.
KR101048748B1 (ko) 신규 갈바닉산 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 다약제내성 억제용 약학적 조성물
CN115594707A (zh) 附子生物碱衍生物及其在制备抗炎药物中的用途
CN116836216A (zh) 氟维司群衍生物及其制备方法和医药用途
HK1220114B (en) Oxprenolol compositions for treating cancer
CN101264082A (zh) 治疗胃损伤的化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120725

Termination date: 20121227